HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib minor resection study ...
FAYETTEVILLE, GA, UNITED STATES, January 26, 2026 /EINPresswire.com/ -- Postoperative recurrence remains the main ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results